Comparison of gene-expression profiles in parallel bone marrow and peripheral blood samples in acute myeloid leukaemia by real-time polymerase chain reaction.

Journal of Clinical Pathology
E SakhiniaR J Byers

Abstract

Gene signatures (Indicator genes) in bone marrow that provide more precise prognostication in haematological malignancy have been identified by microarray expression studies. It would be beneficial to measure these diagnostic signatures in peripheral blood. To determine the degree of correspondence of gene expression for a set of Indicator genes between bone marrow and peripheral blood in acute myeloid leukaemia (AML). Parallel bone marrow aspirate and peripheral blood samples were obtained from 19 patients diagnosed with AML and mononuclear cells isolated from both sample types. mRNA was globally amplified by polyadenylated real-time polymerase chain reaction (polyA RT-PCR); the expression of 15 AML Indicator genes, identified from previous microarray studies, was measured by RT-PCR. All values were normalised to the mean expression of three housekeeping genes (IF2-beta, GAP and RbS9) and were statistically compared using SPSS software. No significant difference in expression between bone marrow and peripheral blood was observed for 10 of the genes (leptin receptor, CD33, adipsin, proteoglycan 1, MB-1, cyclin D3, hSNF2b, proteasome iota, HkrT-1 and E2A), indicating its possible use in monitoring disease activity in peripheral ...Continue Reading

References

Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Apr 16, 2004·The New England Journal of Medicine·David Grimwade, Torsten Haferlach
May 25, 2004·Blood·Benjamin L Ebert, Todd R Golub
Aug 24, 2004·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Richard ByersJudith Hoyland
Jul 21, 2005·British Journal of Haematology·Ebrahim SakhiniaRichard J Byers

❮ Previous
Next ❯

Citations

May 23, 2012·Genome Research·Suhaida A SelamatIte A Laird-Offringa
Aug 22, 2008·Blood·Klaus H MetzelerUNKNOWN German AML Cooperative Group
Nov 15, 2012·BMC Bioinformatics·Hongyan ZhangZheming Yuan
Feb 10, 2010·Leukemia & Lymphoma·Fabián A TedeschiFabián E Zalazar
Apr 1, 2008·Expert Opinion on Medical Diagnostics·Mitch Raponi, Jean-Luc Harousseau
Dec 6, 2008·British Journal of Haematology·Alice M S CheungAnskar Y H Leung

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.